Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021
July 9, 2021
Julia W. Gargano, PhD,*; Megan Wallace, DrPH,*; Stephen C. Hadler, MD; Gayle Langley, MD; John R. Su, MD, PhD; Matthew E. Oster, MD; Karen R. Broder, MD; Julianne Gee, MPH; Eric Weintraub, MPH; Tom Shimabukuro, MD; Heather M. Scobie, PhD; Danielle Moulia, MPH; Lauri E. Markowitz, MD; Melinda Wharton, MD; Veronica V. McNally, JD; José R. Romero, MD; H. Keipp Talbot, MD; Grace M. Lee, MD; Matthew F. Daley, MD; Sara E. Oliver, MD.
This CDC Morbidity and Mortality Weekly Report summarized ACIP’s recommendations on the use of Pfizer and Moderna mRNA COVID-19 vaccines following reports of myocarditis. Out of 296 million mRNA vaccine doses administered in the United States thus far, 1,226 reports of myocarditis following vaccination were reported between December 29, 2020, and June 11, 2021. For the 1,194 reports with available information, 687 were among individuals younger than 30 years old, and 923 were male. Among those younger than 30 years which CDC further reviewed, 96% were hospitalized. However, 95% had been discharged at the time of this analysis, and there had been no deaths. ACIP conducted a benefit-risk assessment of COVID-19 vaccination, considering the reduction of COVID-19 cases, hospitalizations, and deaths. This assessment resulted in the ACIP recommending that COVID-19 vaccine benefits outweigh the risks for all age groups. There will be continual monitoring of adverse events, and providers are to be informed of potential risks.
Gargano JW. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 977–82.